This is not something an otherwise very healthy (to say nothing of well-heeled) person would do -- they would have their specialist MD enroll them in one of a dozen studies underway, to get access to these experimental meds.
In any event, we saved this tidbit for a Sunday -- as it is not really Earth-shattering news: the rich and powerful in the US regularly get very special health care treatment. But in this case, the American people are entitled to know if the guy at 1600 Penn is far more frail than he is letting on. [Where are his actual physical results -- from an unaffiliated MD -- not his stupid press-bites. . . and, while we are at it. . . his. . . tax returns?!]
Here is the story from STAT+ that spread like wildfire last week -- prompting Congressional inquiries:
. . .Millions of Americans with obesity are eagerly awaiting a powerful new drug from Eli Lilly called retatrutide, which has demonstrated bariatric-surgery levels of weight loss. Some aren’t even waiting for approval from the Food and Drug Administration, instead racing to acquire it through sketchy means.
But STAT has learned that Eli Lilly and the FDA have allowed one person to gain access to the drug through the FDA’s “compassionate use” program, a pathway that gives patients with serious and immediately life-threatening medical issues access to experimental treatments. . . .
Ultimately, for the overall US health care narrative arc, this one case is perhaps trivial -- but if the most powerful can access pathways that were supposedly reserved for the most dire, and needy cases. . . once again, we are compelled to point out that the US health care delivery system is. . . fundamentally flawed. Onward.
नमस्ते
No comments:
Post a Comment